Acronym: Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT2 Inhibitors

Purpose: Researchers compared cardiovascular and mortality outcomes associated with SGLT2 inhibitors vs. other glucose-lowering medications in patients with type 2 diabetes

Format: Observational, cohort, retrospective

Treatment Group: SGLT2 inhibitors

Control Group: Other glucose-lowering medications

Number of Participants: 470,128

Centers: Multicenter

Inclusion Criteria: Patients with established type 2 diabetes who were new users of SGLT2 inhibitors or other glucose-lowering drugs


  • Hospitalization for heart failure
  • All-cause death
  • Myocardial infarction
  • Stroke
  • Composite endpoint of all-cause death or hospitalization for heart failure.

Summary: Compared with the other glucose-lowering drugs, SGLT2 inhibitors decreased the risk for all-cause death (HR = 0.51; 95% CI, 0.37-0.7) and hospitalization for heart failure (HR = 0.64; 95% CI, 0.5-0.82). Patients taking SGLT2 inhibitors had lower risk for the composite of all-cause death or heart failure hospitalization vs. those taking other glucose-lowering drugs (HR = 0.6; 95% CI, 0.47-0.76). The risk for myocardial infarction decreased in patients taking SGLT2 inhibitors vs. those taking other glucose-lowering drugs (HR = 0.81; 95% CI, 0.74-0.88). This was also seen with the risk for stroke (HR = 0.68; 95% CI, 0.55-0.84).

Original Publication:

Kosiborod M, et al. J Am Coll Cardiol. 2018;doi:10.1016/j.jacc.2018.03.009.

Link to Cardiology Today Article: